NTRC is a privately owned biotech company based in Oss, The Netherlands, established by former employees of MSD/Organon. NTRC translates novel biological concepts on the treatment of diseases into small molecule drug candidates. NTRC has a strong academic network that it leverages to identify new and innovative approaches for small molecule drug discovery. NTRC has developed a number of breakthrough technology platforms. These platforms are available for clients as NTRC Services.
Area of work
Drug discovery, Drug development, Oncology, Cancer Cell Panel Profiling, Binding kinetics, Assay reagents
- Oncolines™: Profiling of one compound in parallel on a panel of 102 human cancer cell line proliferation assays.
A compound can be a small molecule, a biologic, or anti-body drug conjugate. The cancer cell lines are characterized with regard to the presence or absence of more than hundred cancer genes. Correlation of cancer cell line sensitivity and genotype is used to identify novel drug sensitivity biomarkers that can be used for patient stratification.
- SynergyFinder™: Testing of combinations of compounds in Oncolines™ cell proliferation assays. Studies can be small combination studies or large SynergyScreens™.
- ResidenceTimer™: Measurement of association and dissociation rate constant (which is the inverse of the target residence time) of compounds binding to protein kinases. Currently, assays are available for more than sixty kinases.
- NFK Green™: Assay reagent to measure the activity of tryptophan metabolizing enzymes IDO1 and TDO, which are two important cancer immunotherapy drug targets. NTRC sells biochemical and cell-based assays kits to its customers worldwide.
NTRC offers internship positions for bachelor and master students in (medical) biology and medicinal chemistry.